Assembly committee hears SB 418 to codify ACA nondiscrimination protections and allow 12‑month hormone supplies

The Assembly Business and Professions Committee on Wednesday heard SB 418 (Menjivar), a bill that would (1) codify Section 1557 of the Affordable Care Act into California law as a protection against discrimination in government‑funded health programs and (2) require pharmacists to dispense up to a 12‑month supply of prescriptive hormone therapy when a provider has authorized a 12‑month dispense and the plan covers it.

Proponents told the committee the measure would reduce interruptions in medically approved hormone therapy and relieve families who fear sudden loss of access. "There has been a lot of misleading and false information coming down on gender affirming care that has had some grave consequences here in California," Senator Menjivar said when introducing the bill and noted the measure reflects amendments agreed in prior health committee hearings. Parent and advocate Shana Kirk said providing a larger supply could prevent families from feeling forced to seek "less than reliable alternatives" or from stockpiling and rationing medication. Dr. Denise Taylor, a board‑certified family physician, cited clinical guidance and research linking access to gender‑affirming care with reduced suicidality and said a 12‑month supply would help patients avoid monthly encounters that some find discriminatory at the pharmacy counter.

A range of medical and advocacy organizations spoke in support, including Rainbow Families Action, Equality California, Planned Parenthood Affiliates of California, the Western Center on Law and Poverty, the California Academy of Family Physicians and others. No witnesses registered opposition during the hearing.

The sponsor described narrow conditions: the 12‑month dispensing would apply only "when medically approved, only when the provider has allowed 12 months worth of dispensement, and [the supply] be covered by the health plans with the sunset date of January 2035." The author also said the bill codifies the cited federal nondiscrimination provision in response to federal executive‑branch actions that, in the sponsor’s view, had created uncertainty about protections.

The committee did not record extended debate; Senator Menjivar and committee members expressed support, and the author asked for an "I" vote when the committee took the consent calendar. The bill was moved out of committee as amended to the Committee on Appropriations.